

B3
--31. The method of claim 30, wherein said autoimmune disease is multiple sclerosis.--

REMARKS

Claims 1-16 and 19-31 are pending. Claims 17 and 18 are canceled; claim 12 is amended; and claims 19-31 are added herein.


Claims 19-23 are directed to subject matter deleted by the previous removal of multiple dependencies from the claims. Claims 24-31 are directed to subject matter corresponding to canceled use claims 17 and 18. Claim 12 is amended to remove an improper dependency. However, the subject matter deleted from the claim has been reintroduced by the addition of claim 20.

The attached paper copy and computer-readable copy of the Sequence Listing are submitted in compliance with 37 C.F.R. §§1.821-1.825. The contents of the paper copy and the computer-readable copy of the Sequence Listing are the same. No new matter is added. Support for the information provided in the Sequence Listing can be found in the original Sequence Listing and in the specification at page 4.

2347

Prompt and favorable consideration on the merits is respectfully requested.

Respectfully submitted,


William P. Berridge
Registration No. 30,024

Melanie L. Mealy
Registration No. 40,085

WPB:MLM/jca

Attachments:

Appendix
Sequence Listing (paper and computer-readable copies)

Date: October 22, 2001

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE
AUTHORIZATION
Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461

APPENDIX

Changes to Specification:

The Sequence Listing is replaced.

The following is a marked-up version of the amended paragraph:

Page 4, line 13 - page 5, line 18:

Location of the clones on the reconstructed genomic RNA sequence:

cl.6A2 (1321 bp) 1-1325;

cl.PH74 (535+2229= 2764 bp) 72-606 and 5353-7582;

cl.24.4 (491+1457= 1948 bp); 115-606 and 5353-6810;

cl.44.4 (2372 bp) 115-2496;

cl.PH7 (369+297= 666 bp) 237-606 and 7017-7313; cl.6A1 (2938 bp) 586-3559;

cl.Pi5T (2785+566= 3351 bp) 2747-5557 and 7017-7582;

cl.7A16 (1422 bp) 2908-4337;

cl.Pi22 (317+1689= 2006 bp) 3957-4273 and 4476-6168;

cl.C4C5 (1116 bp) 6467-7582

5'LTR 1..120

/note="R of 5'LTR (5' end uncertain)~~sie~~"

121..575

/note="U5 of 5'LTR"

misc. 579..596

/note="PBS, primer binding site, for tRNA-W"

misc. 606

/note="splice junction (splice donor site ATCCAAAGTG-GTGAGTAATA
(SEQ ID NO: 32) and splice acceptor site CTTTTTCAG-ATGGGAAACG
(SEQ ID NO: 33), clone RG083M05, GenBank accession AC000064)"

misc. 5353

/note="splice acceptor site for ORF1 (env)"

misc. 5560

/note="splice donor site"

ORF 5581..7194

/note="ORF1 env 538 AA"

/product-="envelope"

misc. 7017

/note="splice acceptor site for ORF2 and ORF3"

ORF 7039..7194

/note="ORF2 52 AA"

ORF 7112..7255

/note="ORF3 48 AA"

misc. 7244..7254

/note="PPT, polypurine tract"

3'LTR 7256..7582

/note="U3-R of 3' LTR (U3-R junction undetermined)

misc. 7563..7569

polyadenylation signal

Changes to Claims:

Claims 17 and 18 are canceled.

Claims 19-31 are added.

The following is a marked-up version of the amended claim:

12. (Amended) Method for studying and/or monitoring T-cell proliferation in vitro, according to which the T cells from a patient are brought into contact with either ~~transcription/translation products, as obtained according to the method of claim 11, or~~ synthetic peptides belonging to SEQ ID NO. 31.

T007T0072266660